Veganz Group AG: Founding of OrbiFarm GmbH in Preparation for the Entry of a Strategic Investor in Q2/2025

Advanced talks with six investor groups - OrbiFarm post-money valuation: around EUR 40 million

Ludwigsfelde (pta010/14.04.2025/08:00 UTC+2)

Disclosure of inside information pursuant to Article17 (1) of the Regulation (EU) 596/2014 on market abuse (market abuse regulation)

NOT FOR RELEASE, PUBLICATION, DISTRIBUTION, DISSEMINATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION, DISSEMINATION OR TRANSMISSION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.

Veganz Group AG: Founding of OrbiFarm GmbH in preparation for the entry of a strategic investor in Q2/2025

Advanced talks with six investor groups - OrbiFarm post-money valuation: around EUR 40 million

(Ludwigsfelde, 14 April 2025, 8:00 am) - Veganz Group AG (WKN: A3E5ED / symbol: VEZ) founded OrbiFarm GmbH ('OrbiFarm') on 10 April 2025 in order to leverage hidden reserves within the company. The purpose of the company is the research, development, patenting, production, distribution and licensing of indoor farming technologies. The focus is on the cultivation of protein plants and medicinal plants on an industrial scale. These include peas, amaranth, quinoa, hemp and okra, as well as tobacco plants (insulin production) and other medicinal plants.

Following the planned entry of a strategic investor with an investment of EUR 10.0 million, Veganz Group AG will still hold a majority stake of 74.9 per cent in OrbiFarm. The new investor will receive a blocking minority of 25.1 per cent.

The worldwide exclusive licences of the Fraunhofer patents for the OrbiLoop® and OrbiPlant® technology, the biopatents for the seeds and plants as well as the brand and OrbiFarm LLC, based in Dubai, which acts as a sales organisation for the MENA region, will be transferred from Veganz Group AG to OrbiFarm. OrbiFarm will finance the construction of a prototype facility at the Fraunhofer Institute for Molecular Biology and Applied Ecology IME ('Fraunhofer Institute') in Aachen and launch the first projects for the construction of farms for medicinal plants and protein products.

With the innovative OrbiFarm® technology platform, high-quality staple foods and medicinal plants can be cultivated in a hall anywhere in the world, regardless of climatic and environmental influences, in a cost-effective and economically viable manner (vertical indoor farming).

The results from the OrbiFarm® cultivation trials with pea plants at the Fraunhofer Institute were very successful in terms of yield, quality, reproducibility, safety and cost-effectiveness. The yield was up to 36 times higher than with conventional cultivation and could be further optimised by CO2 fumigation, for example.

Thanks to the entry of a new shareholder in OrbiFarm, the construction of the first industrial-scale plant can be financed. Construction is planned at the site of the Fraunhofer Institute in Aachen. It is providing a suitable building for this purpose. Körber Technologies GmbH is responsible for the design and production.

Plants for pharmaceutical use as well as alternative protein plants for the first customers will be grown at this site. At present, there are already seven (7) concrete projects for the construction of OrbiFarm plants from all over the world.

OrbiFarm was set up as a lean licensing model and will not build or operate any plants itself. The design, production, construction and maintenance will be carried out by Körber Technologies GmbH, which currently has 13,000 employees worldwide. The licence fees are calculated both on the sale of the OrbiFarm systems and on the operators' annual revenue.

In 2024, the market for alternative proteins was estimated at USD 18.58 billion. This market is expected to grow to USD 74.67 billion by 2037. The compound annual growth rate (CAGR) is around 11.2 per cent in the forecast period 2025 - 2037.

Contact Company:

Veganz Group AG
An den Kiefern 7
14974 Ludwigsfelde
Phone: +49 (0)30 2936378 0
E-mail: info@veganz.de

Contact Investor Relations:
Massimo Garau (Chief Financial Officer, CFO)
Phone: +49 (0)151 46569362
E-mail: ir@veganz.de

IMPORTANT NOTICE

This publication may not be released, published, distributed, disseminated or transmitted in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, Japan, South Africa or any other jurisdiction in which such release, publication, distribution dissemination, or transmission would be unlawful. This publication constitutes neither an offer to sell nor a solicitation to buy shares or other securities of Veganz Group AG. There will be no public offering of shares or other securities of Veganz Group AG. The shares of Veganz Group AG have not been and will not be registered under the U.S. Securities Act of 1933, as amended.

(end)

Emitter:	Veganz Group AG An den Kiefern 7 14974 Ludwigsfelde Germany
Contact Person:	Massimo Garau
Phone:	+49 30 2936378-0
E-Mail:	ir@veganz.de
Website:	www.veganz.de
ISIN(s):	DE000A254NF5 (Bond) DE000A3E5ED2 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate